In recent years, the chances of successfully treating breast cancer are increasingly increasing and today the disease can be cured definitively in most cases, thanks to the availability of new and effective targeted therapies and diagnostic technologies. advanced as genetic tests.
As with all neoplasms, for breast cancer, after surgery and subsequent adjuvant therapies, it is necessary to adopt a lifestyle that requires constant attention to periodic reviews and correct follow-up, which should be approached with serenity and with the knowledge that there will not necessarily be a return of the pathology.
Increasingly important are the so-called “genetic markers”, performed with laboratory tests capable of identifying variations in the genetic material (DNA, RNA) present in the samples of patients with tumors, such as the breast. These genetic tests, associated with common diagnostic procedures, today allow a reliable prognosis of prognosis, better quality of life management and the choice of optimal treatments for each patient, eliminating the occurrence of possible recurrences.
The progressive improvement of technologies now allows evaluating not only a genetic marker, but more markers or marker panels at the same time, providing accurate, detailed and detailed information on the characteristics of the individual tumor for each patient.
If until today in general we have talked about “breast cancer”, with these technologies we can now have an accurate image of it and know each specific element that constitutes the unique, individual and exclusive profile of each individual tumor, for each patient.
Prosigna, in particular, based on the expression of 50 genes, can offer the oncologist useful information to identify cases in which chemotherapy can be avoided. This is an in vitro diagnostic analysis that uses the gene expression profile of the cells detected in the mammary tumor tissue to determine the risk of recurrence of the patient at a distance and, therefore, allows the genetic classification of breast tumors and the simultaneous evaluation of the risk recurrence category of cancer at 10 years.
It is a tool that aims to allow breast cancer patients to receive a “personalized” diagnostic and therapeutic framework, which allows them to predict the risk of remote recurrence for each patient and, therefore, evaluate the opportunity for a treatment. of chemotherapy Prosigna is not the only test that can predict the risk of breast cancer recurrence, but it is the only one that combines molecular analysis with the patient’s clinical data.
The test is indicated for those postmenopausal patients suffering from breast cancer who have already undergone surgery with positive hormonal receptor (HR +), with a state of lymph nodes in stage 0 negative or positive, I (1-3 positive lymph nodes) or belonging to stage II or IIIA.